---
title: "Atea Pharmaceuticals, Inc. (AVIR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AVIR.US.md"
symbol: "AVIR.US"
name: "Atea Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T13:31:02.348Z"
locales:
  - [en](https://longbridge.com/en/quote/AVIR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AVIR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AVIR.US.md)
---

# Atea Pharmaceuticals, Inc. (AVIR.US)

## Company Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [ateapharma.com](https://ateapharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.98 | 130 | - | - | - |
| PB | 1.43 | 72 | 1.42 | 0.78 | 0.69 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |
| Hold | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.24 |
| Highest Target | 10.50 |
| Lowest Target | 6.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AVIR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AVIR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AVIR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AVIR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**